Skip to main content
OpenTrials

Clinical trial condition

Diabetes Mellitus, Type 2

Explore clinical trials studying Diabetes Mellitus, Type 2. Study availability and eligibility vary by location and protocol.

8,001 public trials 713 recruiting studies
Refine in advanced search Browse all conditions

Diabetes Mellitus, Type 2 trial results

Completed

Study In People With Type 2 Diabetes

NCT00196989

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Northport, Alabama, United States
  • GSK Investigational Site Chandler, Arizona, United States
  • GSK Investigational Site Phoenix, Arizona, United States
View all 143 locations
View Trial Details
Completed

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

NCT01814137

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Goodyear, Arizona, United States
  • Novo Nordisk Investigational Site Phoenix, Arizona, United States
  • Novo Nordisk Investigational Site Anaheim, California, United States
  • Novo Nordisk Investigational Site Greenbrae, California, United States
View all 40 locations
View Trial Details
Completed

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes

NCT01045447

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Fresno, California, United States
  • Novo Nordisk Investigational Site Waterbury, Connecticut, United States
  • Novo Nordisk Investigational Site Boynton Beach, Florida, United States
  • Novo Nordisk Investigational Site Clearwater, Florida, United States
View all 65 locations
View Trial Details
Completed

A Study of LY2405319 in Participants With Type 2 Diabetes

NCT01869959

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Cypress, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tustin, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. DeLand, Florida, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Miramar, Florida, United States
View Trial Details
Completed

Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

NCT00614055

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Alès, France
  • Novo Nordisk Investigational Site Brest, France
  • Novo Nordisk Investigational Site La Rochelle, France
  • Novo Nordisk Investigational Site Le Creusot, France
View all 28 locations
View Trial Details
Completed

Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

NCT00613951

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Helsinki, Finland
  • Novo Nordisk Investigational Site Kuopio, Finland
  • Novo Nordisk Investigational Site Lahti, Finland
  • Novo Nordisk Investigational Site Pori, Finland
View all 31 locations
View Trial Details
Completed

Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes

NCT01272193

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Asahikawa-shi, Hokkaido, Japan
  • Novo Nordisk Investigational Site Chigasaki-shi, Kanagawa, Japan
  • Novo Nordisk Investigational Site Chuo-ku, Tokyo, Japan
  • Novo Nordisk Investigational Site Chuo-ku, Tokyo, Japan
View all 50 locations
View Trial Details
Completed

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

NCT01365507

Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, +4 more
Locations
  • Novo Nordisk Investigational Site Concord, California, United States
  • Novo Nordisk Investigational Site Los Angeles, California, United States
  • Novo Nordisk Investigational Site Montclair, California, United States
  • Novo Nordisk Investigational Site Palm Springs, California, United States
View all 42 locations
View Trial Details

Related conditions